These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22120094)

  • 1. Phase III clinical pharmacology study of tolvaptan.
    Inomata T; Izumi T; Matsuzaki M; Hori M; Hirayama A;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S57-65. PubMed ID: 22120094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Matsuzaki M; Hori M; Izumi T; Asanoi H; Tsutamoto T;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S19-31. PubMed ID: 22120091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study.
    Fukunami M; Matsuzaki M; Hori M; Izumi T;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S47-56. PubMed ID: 22120093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
    Matsuzaki M; Hori M; Izumi T; Fukunami M;
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
    Kim SR; Hasunuma T; Sato O; Okada T; Kondo M; Azuma J
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S5-17. PubMed ID: 22120090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
    Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study.
    Kida K; Shibagaki Y; Tominaga N; Matsumoto N; Akashi YJ; Miyake F; Kimura K
    Clin Pharmacokinet; 2015 Mar; 54(3):273-84. PubMed ID: 25305049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
    Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.
    Takagi K; Sato N; Ishihara S; Iha H; Kobayashi N; Ito Y; Nohara T; Ohkuma S; Mitsuishi T; Ishizuka A; Shigihara S; Sone M; Nakama K; Tokuyama H; Omote T; Kikuchi A; Nakamura S; Yamamoto E; Ishikawa M; Amitani K; Takahashi N; Maruyama Y; Imura H; Shimizu W
    J Cardiol; 2020 Nov; 76(5):499-505. PubMed ID: 32665162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study.
    Sakaida I; Yanase M; Kobayashi Y; Yasutake T; Okada M; Okita K;
    J Int Med Res; 2012; 40(6):2381-93. PubMed ID: 23321196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.
    Nishi H; Toda K; Miyagawa S; Yoshikawa Y; Fukushima S; Kawamura M; Yoshioka D; Saito T; Ueno T; Kuratani T; Sawa Y
    Surg Today; 2015 Dec; 45(12):1542-51. PubMed ID: 26411431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1395-1403. PubMed ID: 29934667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
    Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15- to 60-mg single doses to healthy Korean men.
    Yi S; Jeon H; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Cardiovasc Pharmacol; 2012 Apr; 59(4):315-22. PubMed ID: 22130104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.